Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut
(Reuters) -Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million. The company's shares opened at $16.12 apiece, ...
thepoultrysite1h
Weekly global protein digest: Smithfield raises $522 million in IPO, Historic US cash cattle surge continues
Weekly USDA US beef, pork export sales. Beef: Net US sales of 20,200 MT for 2025 were primarily for South Korea (11,300 MT, ...
GlobalCapital1h
Diagnostyka prices Z1.7bn IPO at top of range
Diagnostyka Group, the Polish medical diagnostics company, completed its IPO bookbuild on Friday and priced the deal at the ...
Fresh Take: Smithfield IPO Initially Disappoints Amid Rollercoaster Week
Forbes' latest edition of its Fresh Take newsletter covers a busy week in Washington, Smithfield's IPO, egg and Super Bowl ...
Biotech firm Maze Therapeutics raises $140 million in US IPO
Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...
GlobalCapital20h
IPO investors and issuers may still be too far apart
Add in fears of economic slowdown, lingering inflation, and an uncertain rate path and IPO investors can be forgiven for ...